Back to Journals » International Journal of Women's Health » Volume 4

Weight reduction and pioglitazone ameliorate polycystic ovary syndrome after removal of a Sertoli-stromal cell tumor

Authors Baba T , Endo T, Ikeda, Shimizu, Morishita, Kuno, Honnma, Kiya, Ishioka, Saito

Received 3 August 2012

Accepted for publication 6 September 2012

Published 23 November 2012 Volume 2012:4 Pages 607—611


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Tsuyoshi Baba,1 Toshiaki Endo,1 Keiko Ikeda,1 Ayumi Shimizu,1 Miyuki Morishita,1 Yoshika Kuno,1 Hiroyuki Honnma,2 Tamotsu Kiya,3 Shin-ichi Ishioka,1 Tsuyoshi Saito1

1Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, 2Asada Ladies Clinic, Kasugai, Aichi, 3Ena Ladies Clinic, Ishikari, Hokkaido, Japan

Abstract: This report presents an unusual case of Sertoli-stromal cell tumor and polycystic ovary syndrome successfully treated with weight reduction and an insulin-sensitizing agent. A 22-year-old woman, gravida 0, para 0, visited our hospital for the first time with a 12-year history of secondary amenorrhea and hypertrichosis. Transvaginal ultrasonography revealed a solid tumor in the right ovary. Right salpingo-oophorectomy was performed and pathological examination confirmed a Sertoli-stromal cell tumor. The patient's serum androgen levels declined postoperatively, but remained above normal. Pioglitazone treatment for 6 months also significantly reduced serum androgen levels, but they still remained above normal. However, after losing 12 kg of body weight, the patient's serum androgen levels declined to normal, and spontaneous menstruation became regular. Weight reduction with pioglitazone is an effective means of treating hyperandrogenism.

Keywords: etiology, hyperandrogenism, pioglitazone, polycystic ovary syndrome, Sertoli-stromal cell tumor, weight reduction

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.